Accelerate Fund III has invested in PulseMedica, a cutting-edge Edmonton medical device firm focused on developing advanced laser treatment solutions for vitreoretinal eye diseases affecting over 500 million people globally.
Target Information
Accelerate Fund III has announced its investment in PulseMedica, an innovative Edmonton-based medical device company revolutionizing the approach to treating vitreoretinal eye diseases. PulseMedica is pioneering a cutting-edge 3D imaging and surgical system capable of delivering ultra-precise laser treatments for conditions that affect over 500 million individuals globally.
The company’s proprietary ophthalmic laser technology seeks to address several challenging conditions, including vitreous floaters, diabetic retinopathy, age-related macular degeneration (AMD), branch retinal vein occlusion, and vitreomacular traction. Earlier in the year, PulseMedica successfully completed its first clinical trial focused on diabetic retinopathy, showcasing the effectiveness, safety, and precision of its imaging and treatment platform.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Canada
The medical device industry in Canada represents an essential sector within the broader healthcare landscape, contributing significantly to both economic growth and patient care advancements. The countr
Similar Deals
Sectoral Asset Management, Genesys Capital, Desjardins Capital, Seido Capital, Private Investors → Antegrade Medical Inc.
2025
Accelerate Fund III
invested in
PulseMedica
in 2023
in a Seed Stage deal
Disclosed details
Transaction Size: $1M